Literature DB >> 26868356

Research methods to change clinical practice for patients with rare cancers.

Lucinda Billingham1, Kinga Malottki2, Neil Steven3.   

Abstract

Rare cancers are a growing group as a result of reclassification of common cancers by molecular markers. There is therefore an increasing need to identify methods to assess interventions that are sufficiently robust to potentially affect clinical practice in this setting. Methods advocated for clinical trials in rare diseases are not necessarily applicable in rare cancers. This Series paper describes research methods that are relevant for rare cancers in relation to the range of incidence levels. Strategies that maximise recruitment, minimise sample size, or maximise the usefulness of the evidence could enable the application of conventional clinical trial design to rare cancer populations. Alternative designs that address specific challenges for rare cancers with the aim of potentially changing clinical practice include Bayesian designs, uncontrolled n-of-1 trials, and umbrella and basket trials. Pragmatic solutions must be sought to enable some level of evidence-based health care for patients with rare cancers.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26868356     DOI: 10.1016/S1470-2045(15)00396-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  38 in total

Review 1.  Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

Authors:  Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal
Journal:  Nat Rev Clin Oncol       Date:  2017-05-16       Impact factor: 66.675

2.  Quality of Randomized Controlled Trials Reporting in the Treatment of Adult Patients with High-Grade Gliomas.

Authors:  Magalie P Tardy; Jocelyn Gal; Emmanuel Chamorey; Fabien Almairac; Fanny Vandenbos; Pierre-Yves Bondiau; Esma Saada-Bouzid
Journal:  Oncologist       Date:  2017-11-13

3.  Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.

Authors:  Hiroki Nakayama; Katsura Tsukamoto
Journal:  Invest New Drugs       Date:  2018-04-17       Impact factor: 3.850

4.  A Bayesian basket trial design using a calibrated Bayesian hierarchical model.

Authors:  Yiyi Chu; Ying Yuan
Journal:  Clin Trials       Date:  2018-03-02       Impact factor: 2.486

5.  Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.

Authors:  Ana Collazo-Lorduy; Mireia Castillo-Martin; Li Wang; Vaibhav Patel; Gopa Iyer; Emmet Jordan; Hikmat Al-Ahmadie; Issa Leonard; William K Oh; Jun Zhu; Russell B McBride; Carlos Cordon-Cardo; David B Solit; John P Sfakianos; Matthew D Galsky
Journal:  Eur Urol       Date:  2016-05-10       Impact factor: 20.096

Review 6.  Advances in the molecular genetics of gliomas - implications for classification and therapy.

Authors:  Guido Reifenberger; Hans-Georg Wirsching; Christiane B Knobbe-Thomsen; Michael Weller
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

Review 7.  Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.

Authors:  L A Renfro; D J Sargent
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

8.  IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities.

Authors:  Florian Pohlig; Ulrich Lenze; Heinrich M L Muhlhofer; Florian W Lenze; Johannes Schauwecker; Carolin Knebel; Tanja Zimmermann; Peter Herschbach
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 9.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

10.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.